Dyne therapeutics logo
WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1).
Dyne therapeutics logo
Did you know?
WebMay 7, 2024 · Dyne Therapeutics' cash burn of US$59m is about 6.4% of its US$916m market capitalisation. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a ... WebMar 2, 2024 · Dyne Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39509 36-4883909 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number ...
WebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … WebMay 14, 2024 · In January 2024, Dyne reported data showing that two doses (2 x 10 mg/kg) of its lead DM1 candidate resulted in significant toxic human nuclear DMPK knockdown at 14 days. New data being presented ...
WebNov 3, 2024 · - DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Underway with Data Anticipated in the Second Half of 2024 - WALTHAM, Mass., Nov. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people … WebApr 10, 2024 · 5 brokerages have issued twelve-month target prices for Dyne Therapeutics' shares. Their DYN share price forecasts range from $18.00 to $34.00. On average, they expect the company's stock price to reach $25.83 in the next year. This suggests a possible upside of 175.4% from the stock's current price.
WebDec 15, 2024 · The Trade: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes acquired a total of 934,581 shares at an average price of $10.70. To acquire these shares, it cost around $10 million. What ...
WebJan 14, 2024 · --Dyne Therapeutics, Inc., a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S ... cincinnati bearcats sportsWebWho invested in Dyne Therapeutics? Dyne Therapeutics has 9 investors including Logos Capital and Wellington Management. How much funding has Dyne Therapeutics raised … cincinnati bearcats transfer portalWebOct 4, 2024 · Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, visits ... cincinnati bearcats symbolWebApr 11, 2024 · Dyne Therapeutics Stock Performance. NASDAQ DYN opened at $8.82 on Tuesday. The stock has a market cap of $496.90 million, a price-to-earnings ratio of -2.72 and a beta of 0.24. cincinnati bearcats team shopWebApr 3, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyne Therapeutics, a new biotechnology company pioneering targeted therapies for patients with serious muscle diseases, launched today with a $50 million Series ... cincinnati bearcats sweatshirtsWebDyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary ... cincinnati bearcats tournament shortsWebMar 14, 2024 · 天眼查为您提供Dyne Therapeutics Inc.的企业信息查询服务，查询Dyne Therapeutics Inc.工商注册信息、公司电话、公司地址、公司邮箱网址、公司经营风险、公司发展状况、公司财务状况、公司股东法人高管、商标、融资、专利、法律诉讼等Dyne Therapeutics Inc.企业信用信息，想了解Dyne Therapeutics Inc.怎么样，就 ... cincinnati bearcats tickets